Ge11-Modified pH-Sensitive Polymer Micelles: A New Breakthrough in Targeted Therapy for Non-Small-Cell Lung Cancer

Area of Science:

• Biomedical Engineering
• Nanotechnology
• Oncology

Background:

• Lung cancer treatment faces challenges in drug delivery, including low tumor concentration, reduced efficacy, and systemic toxicity.
• Targeted drug delivery systems aim to overcome these limitations by concentrating therapeutics at the tumor site.
• Responsive nanocarriers offer controlled drug release mechanisms tailored to the tumor microenvironment.

Purpose of the Study:

• To develop an intelligent, pH-responsive polymer micelle system (GPDD) for enhanced lung cancer drug delivery.
• To achieve targeted accumulation and controlled release of antitumor drugs at lung tumor sites.
• To improve therapeutic efficacy while minimizing systemic toxicity.

Main Methods:

• GPDD system formation via self-assembly of GE11-PEG-hyd-DOX conjugates with co-loaded free DOX.
• Utilized GE11 peptide for epidermal growth factor receptor (EGFR) targeting and hydrazone bond for pH-responsive drug release.
• In vitro cytotoxicity assays (CCK-8) and in vivo studies using tumor-bearing nude mouse models.

Main Results:

• GE11-modified GPDD demonstrated effective inhibition of tumor cell growth in vitro.
• In vivo studies showed GPDD achieved superior tumor suppression compared to free DOX and unmodified PDD.
• GPDD exhibited significantly lower systemic toxicity in tumor-bearing mice.

Conclusions:

• The GPDD nanocarrier effectively integrates targeting and pH responsiveness for improved lung cancer therapy.
• This dual-functional design enhances antitumor efficacy and reduces adverse side effects.
• The co-loading strategy and dual-functional design offer novel insights for tumor-targeted delivery systems with translational potential.